Abstract. Background: To improve long-term survival by
reducing toxicity in intermediate stage Hodgkin’s disease
patients, we compared the effects of involved field (IF) versus
extended field (EF) irradiation administered after four cycles of
ABVD regimen. Materials and Methods: Two hundred and ten
Hodgkin’s disease patients, at clinical stage II with risk factors
and III without risk factors, were enrolled in the randomized
study HD94. After four courses of ABVD regimen, patients who
achieved complete remission (CR) or partial remission (PR)
were randomly assigned to the IF or EF arm. The Kaplan-Meier
method was adopted to estimate overall survival (OS) and
relapse-free survival (RFS). Results: After a median follow-up
of 78 months (range 13-111 months), OS was 98% and 96%,
respectively, in the EF and IF arms; RFS was 94% and 91%,
respectively, in the EF and IF arms. Conclusion: We confirm
the efficacy of four cycles of ABVD regimen, with suitable dose
intensity, and radiotherapy as consolidation therapy, in
intermediate stage Hodgkin’s disease patients (CR=99.5% and
OS= 95%). We also found that involved field radiotherapy
results were as effective as extended field, without acute toxicit
